1. Yiu ZZN, Smith CH, Laws P, Hampton PJ, Griffiths CEM, Warren RB; BADBIR Study Group; BSTOP Study Group. Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis. JAMA Dermatol. 2025 Jul 1;161(7):731-738.
2. Phan DB, Lunt M, Warren RB, Yiu ZZN. Switching back to originator adalimumab from biosimilars in psoriasis: A cohort study from BADBIR. J Eur Acad Dermatol Venereol. 2025 Jul;39(7):e621-e624.
3. Motedayen Aval L, Yiu ZZN, Alabas OA, Griffiths CEM, Reynolds NJ, Hampton PJ, Smith CH, Warren RB; BADBIR Study Group. Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study. J Eur Acad Dermatol Venereol. 2025 May 29. doi: 10.1111/jdv.20739. Epub ahead of print.
4. Alabas OA, Evans I, Mcelhone K, Yiu ZZN, Reynolds NJ, Laws PM, Bewley A, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group. Evaluating changes in baseline characteristics and drug utilisation pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) Cohort. Clin Exp Dermatol. 2025 May 22:llaf224. doi: 10.1093/ced/llaf224. Epub ahead of print.
5. Alabas OA, Mason KJ, Yiu ZZN, Smith CH, Warren RB, Griffiths CEM; BADBIR study group. Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2025 Apr 28;192(5):907-916.
6. Phan DB, Bewley AP, Laws P, Mackenzie T, Smith CH, Griffiths CEM, Lunt M, Warren RB, Yiu ZZN. Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis. JAMA Dermatol. 2025 Apr 1;161(4):358-366.
7. Williams K, Lada G, Reynolds NJ, Mcelhone K, Evans I, Warren RB, Walton S, Hughes O, Bewley A, Mason K, Kleyn CE. Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Clin Exp Dermatol. 2025 Mar 26;50(4):804-811.
8. Phan DB, Jourdain H, Descalzo-Gallego MA, González-Quesada A, Zureik M, Rivera-Díaz R, Sahuquillo-Torralba A, Lunt M, Garcia-Doval I, Sbidian E, Warren RB, Yiu ZZN. Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study. Br J Dermatol. 2025 Mar 18;192(4):641-652.
9. Alabas OA, Mason KJ, Yiu ZZ, Warren RB, Dand N, Barker JN, Smith CH, Griffiths CE. The association of age at psoriasis onset and HLA-C* 06: 02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology. 2024 May;190(5):689-700.
10. Mason KJ, Alabas OA, Dand N, Warren RB, Reynolds NJ, Barker JN, Yiu ZZ, Smith CH, Griffiths CE. Characteristics of ‘super responders’ and ‘super nonresponders’ to first biologic monotherapy for psoriasis: a nested case–control study. British Journal of Dermatology. 2024 Mar;190(3):441-4.